tirzepatide compound fda Did the Ban Compounded Semaglutide and Tirzepatide? The FDA is proposing the

Semaglutide is a GLP-1 receptor agonist used for type 2 diabetes management and weight loss, and no antibiotics are contraindicated in its FDA prescribing information

The specific drugs covered are determined by state benchmark plans rather than federal mandate

Patients should seek urgent medical attention if they develop: Severe symptoms including extensive vulval swelling or ulceration Systemic features such as fever Pregnancy with severe symptoms Immunocompromised state with infection Unusual vaginal discharge with offensive odour, particularly if accompanied by pelvic pain, which suggests possible pelvic inflammatory disease requiring prompt antibiotic therapy Any vaginal bleeding outside normal menstruation It is important to note that over-the-counter fluconazole has specific licensing restrictions and may not be available without prescription for all patients

What does genetic testing tell me about the GLP-1 class